Kala Bio Inc (KALA)

$7.25 +0.24 (3.42%)
Market Cap 32.32M
Revenue (ttm) 0.00
Net Income (ttm) -42.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 5.80
Volume 17,500
Avg Vol 37,516
Day's Range N/A - N/A
Shares Out 4.61M
Stochastic %K 46%
Beta -2.11
Analysts Strong Sell
Price Target $15.00

Latest News on KALA

KALA BIO Announces $10,750,000 Private Placement

Dec 30, 2024, 8:00 AM EST - 18 days ago

KALA BIO Announces $10,750,000 Private Placement

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 7 weeks ago

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

KALA BIO to Present at Jefferies Global Healthcare Conference

May 29, 2024, 8:00 AM EDT - 8 months ago

KALA BIO to Present at Jefferies Global Healthcare Conference

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 14, 2024, 4:05 PM EDT - 8 months ago

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 29, 2024, 8:00 AM EDT - 10 months ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

Feb 26, 2024, 8:00 AM EST - 11 months ago

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 19, 2024, 4:01 PM EST - 1 year ago

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 8:00 AM EST - 1 year ago

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 8:00 AM EDT - 1 year ago

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 4, 2023, 8:00 AM EDT - 1 year ago

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

KALA BIO to Participate in Upcoming Investor Conferences in August

Aug 2, 2023, 4:01 PM EDT - 1 year ago

KALA BIO to Participate in Upcoming Investor Conferences in August

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 19, 2023, 4:01 PM EDT - 1 year ago

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

Jun 2, 2023, 8:00 AM EDT - 1 year ago

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 8:00 AM EDT - 1 year ago

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Apr 28, 2023, 8:00 AM EDT - 1 year ago

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Mar 27, 2023, 8:00 AM EDT - 1 year ago

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 8, 2023, 4:01 PM EST - 2 years ago

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 3, 2023, 8:00 AM EST - 2 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Kala Pharma: Rare Eye Disease Biotech Lottery Ticket Based On Stem Cell Platform

Jan 19, 2023, 7:12 AM EST - 2 years ago

Kala Pharma: Rare Eye Disease Biotech Lottery Ticket Based On Stem Cell Platform

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Dec 30, 2022, 12:02 PM EST - 2 years ago

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)

Dec 29, 2022, 8:30 AM EST - 2 years ago

Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Dec 28, 2022, 6:48 AM EST - 2 years ago

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Dec 27, 2022, 4:01 PM EST - 2 years ago

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Nov 28, 2022, 4:02 PM EST - 2 years ago

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Nov 28, 2022, 4:01 PM EST - 2 years ago

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 8, 2022, 8:00 AM EST - 2 years ago

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Nov 1, 2022, 7:30 AM EDT - 2 years ago

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Kala Pharmaceuticals Announces Reverse Stock Split

Oct 20, 2022, 7:30 AM EDT - 2 years ago

Kala Pharmaceuticals Announces Reverse Stock Split

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aug 19, 2022, 4:01 PM EDT - 2 years ago

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Aug 18, 2022, 4:01 PM EDT - 2 years ago

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2022 Results - Earnings Call Transcript

Aug 12, 2022, 7:51 PM EDT - 2 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2022 Results - Earnings Call Transcript

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 11, 2022, 7:00 AM EDT - 2 years ago

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Aug 4, 2022, 4:01 PM EDT - 2 years ago

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Jul 11, 2022, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

Jun 2, 2022, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

Why Kala Pharmaceuticals Shares Are Rising Today

May 23, 2022, 10:17 AM EDT - 2 years ago

Why Kala Pharmaceuticals Shares Are Rising Today

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

May 23, 2022, 12:01 AM EDT - 2 years ago

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call Transcript

May 16, 2022, 10:54 AM EDT - 2 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call Transcript

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 16, 2022, 7:00 AM EDT - 2 years ago

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call

May 9, 2022, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call

Kala Pharmaceuticals Posts KPI-012 Data In Healing Impaired Ocular Diseases

May 2, 2022, 1:25 PM EDT - 2 years ago

Kala Pharmaceuticals Posts KPI-012 Data In Healing Impaired Ocular Diseases

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

May 1, 2022, 9:00 AM EDT - 2 years ago

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting

Apr 4, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q4 2021 Results - Earnings Call Transcript

Mar 29, 2022, 12:10 PM EDT - 3 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q4 2021 Results - Earnings Call Transcript

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Mar 29, 2022, 7:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call

Mar 23, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call

This Microcap Pharma Stock Almost Doubled Today - Read Why

Mar 8, 2022, 4:19 PM EST - 3 years ago

This Microcap Pharma Stock Almost Doubled Today - Read Why

Kala Pharma Acquires Ocular Surface Disease-Focused Company

Nov 15, 2021, 3:15 PM EST - 3 years ago

Kala Pharma Acquires Ocular Surface Disease-Focused Company

Kala Pharmaceuticals' (KALA) CEO Mark Iwicki on Q3 2021 Results - Earnings Call Transcript

Nov 15, 2021, 1:20 PM EST - 3 years ago

Kala Pharmaceuticals' (KALA) CEO Mark Iwicki on Q3 2021 Results - Earnings Call Transcript